Rebound Hypercalcemia Following Discontinuation of Denosumab in a Pediatric Patient: A Case Report

Xian S1, Chang L1, Lijuan Z1, Yalei P1,2, Yuqian L1 and Yanan Z1,2*

1Department of Pediatrics, The Second Hospital of Hebei Medical University, China
2Laboratory of Rare Diseases of Hebei Province, Shijiazhuang, China

^*Correspondance to: Zhang Yanan 

 PDF  Full Text Case Report | Open Access

Abstract:

Denosumab is a human monoclonal antibody approved for the treatment of osteoporosis, giant cell tumor of bone and skeletal metastasis of solid tumors. Rebound hypercalcemia following discontinuation of denosumab is a known side effect that is more frequently reported in skeletally immature patients. We report the case of a 12-year-old female patient with history of giant cell tumor of the cervical spine who was treated with denosumab for almost 2 years. She presented with clinical manifestations related to hypercalcemia more than 5 months after denosumab cessation, the diagnosis was based on bone turnover markers and nuclear medicine scan.

Keywords:

Cite the Article:

Xian S, Chang L, Lijuan Z, Yalei P, Yuqian L, Yanan Z. Rebound Hypercalcemia Following Discontinuation of Denosumab in a Pediatric Patient: A Case Report. Ann Clin Case Rep. 2024; 9: 2643..